Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.
Insider and Institutional Ownership
87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 53.9% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Sagimet Biosciences and Kiniksa Pharmaceuticals International, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sagimet Biosciences | 2 | 1 | 9 | 0 | 2.58 |
| Kiniksa Pharmaceuticals International | 0 | 1 | 8 | 0 | 2.89 |
Volatility and Risk
Sagimet Biosciences has a beta of 3.46, suggesting that its stock price is 246% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500.
Valuation & Earnings
This table compares Sagimet Biosciences and Kiniksa Pharmaceuticals International”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sagimet Biosciences | $2.00 million | 249.26 | -$51.04 million | ($1.28) | -6.27 |
| Kiniksa Pharmaceuticals International | $677.56 million | 9.05 | $59.01 million | $0.97 | 81.02 |
Kiniksa Pharmaceuticals International has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Sagimet Biosciences and Kiniksa Pharmaceuticals International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sagimet Biosciences | N/A | -31.96% | -30.57% |
| Kiniksa Pharmaceuticals International | 9.59% | 13.65% | 10.09% |
Summary
Kiniksa Pharmaceuticals International beats Sagimet Biosciences on 9 of the 14 factors compared between the two stocks.
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
